Analysis of pharmaceutical care in dispensing of over-the-counter orlistat

Česká verzia

Authors: Katarína Dobrucká; Josef Malý; Jiří Vlček
Authors place of work: Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, Katedra sociální a klinické farmacie, Hradec Králové
Published in the journal: Čes. slov. Farm., 2012; 61, 276-281
Category: Original Articles

Summary

Obesity is a chronic disease characterized by its high prevalence. Easy availability of pharmaceutical care allows pharmacies to be the first place of capture or intervention for patients who are overweight or obese. The aim of the study was to analyse the role of pharmacists and pharmacy technicians in securing the safety of self-medication with orlistat. In this prospective observational study, the patients were the people who came to the IKEM Hospital Pharmacy for self-medication with orlistat over a period of May through December 2009. The data were collected by trained pharmacists and pharmacy technicians in interviews with patients when dispensing over-the-counter (OTC) orlistat. The interview was designed by fixed questions. The results were analysed using frequency analysis, GLMz and the chi-square test with the level of significance of p < 0.05. A total of 50 patients participated in the study (44 women, median age 53 years, 41 patients with body mass index > 28). 58% patients were fully indicated for self-medication with orlistat. Self-medication with orlistat was recommended to 48% patients and was refused to 22% patients because of contraindications. 24% patients had at least one interaction with orlistat and chronic drugs. Health problems were the most common motivation for weight reduction. The data obtained in this study demonstrate an important role of pharmacists and pharmacy technicians in the assessment of suitability of self-medication with OTC orlistat and safe weight reduction within self-medication.

Key words:
obesity • pharmaceutical care • orlistat • self-medication

Received 7 November 2012 / Accepted 28 November 2012

Zdroje

1. Armstrong M. J., Mottershead T. A., Ronksley P. E., Sigal R. J., Campbell T. S., Hemmelgarn B. R. Motivational interviewing to improve weight loss in overweight and/or obese patients: a systematic review and meta-analysis of randomized controlled trials. Obes. Rev. 2011; 12, 709–723.

2. Matoulek M., Svačina Š., Lajka J. Výskyt obezity a jejích komplikací v České republice. Vnitř. Lék. 2010; 56, 1019–1027.

3. Berenguer B., La Casa C., de la Matta M. J., Martín-Calero M. J. Pharmaceutical care: past, present and future. Curr. Pharmaceut. Des. 2004; 10, 3931–3946.

4. Kolář J., Macešková B. Současné přístupy k farmakoterapii – farmaceutická péče nebo management léků? Čes. slov. farm. 2010; 59, 7–10.

5. Vlček J., Malý J., Doseděl M. Farmaceutická péče u pacienta s diabetes mellitus a vztah ke klinické farmacii. Vnitř. Lék. 2009; 55, 384–388.

6. Doseděl M., Malý J., Rudolf K. OTC léčiva a samoléčení průjmu a zácpy. Interní Med. 2011; 13, 127–133.

7. Caveney E., Caveney B. J., Somaratne R. Turner J. R., Gourgiotis L. Pharmaceutical interventions for obesity: a public health perspective. Diabetes Obes. Metab. 2011; 13, 490-497.

8. Mikro-verze AISLP, verze 2010.4 pro MS Windows.

9. Anderson J. W. Orlistat for the management of overweight individuals and obesity: a review if potential for the 60 mg, over-the-counter dosage. Exp. Opin. Pharmacother. 2007; 8, 1733–1742.

10. International Diabetic Federation: The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf (22. 10. 2012).

11. Prevost R. R. Pharmacy review: Lifestyle management of obesity: consideration for pharmacists. Am. J. Lifestyle Med. 2007; 1, 451–453.

12. Zadák Z. Výživa v intenzivní péči. 2. vydání. Praha: Grada Publishing 2008; 544s.

13. FIP Statement of Policy the role of the pharmacist in the prevention and treatment of chronic disease. Approved by FIP Council in Brazil in August 2006. http://www.fip.org/www/uploads/database_file.php?id=274&table_id= (25. 9. 2012)

14. Hauptman J., Lucas Ch., Boldrin M. N., Collins H., Segal K. R. Orlistat in the long-term treatment of obesity in primary care settings. Arch. Fam. Med. 2000; 9, 160–167.

15. Le Beller C., Bezie Y., Chabatte C., Guillemain R., Amrein C., Billaud E. M. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000; 70, 1541–1542.

16. Nägele H., Petersen B., Bonacker U., Rödiger W. Effect of orlistat on blood cyclosporine concentration in an obese transplant patients. Eur. J. Clin. Pharmacol. 1999; 55, 667–669.

17. MacWalter R. S., Fraser H. W., Armstrong K. M. Orlistat enhances warfarin effect. Ann. Pharmacother. 2003; 37, 510–512.

18. Ahrens R. A., Hower M., Best A. M. Effects of weight reduction interventions by community pharmacists. J. Am. Pharm. Assoc. 2003; 43, 583–589.

19. Webb M. Weight management interventions by community pharmacists: a rapid review of the evidence. National Public Health Service for Wales, 2009. http://www2.nphs.wales.nhs.uk:8080/pharmaceuticalphtdocs.nsf/Main%20Frameset?OpenFrameSet&Frame=Right&Src=%2Fpharmaceuticalphtdocs.nsf%2F1f8687d8da97650980256fa30051b0be%2Fd694bf1fb94bddbc8025756e004068f1%3FOpenDocument%26AutoFramed (1. 10. 2012).

20. Mikušová K., Kavalírová L., Tlučhořová D., Sovišová P. OTC orlistat – role lékárny v péči o kontrolu tělesné hmotnosti. In: Doporučené postupy České lékárnické komory pro konzultační činnost v lékárnách. Olomouc: Solen, 2010; 121–132.